Charles River Laboratories has launched its triple-immunodeficient mouse model, known as the NCG model. The NCG model is the first CRISPR-generated immunodeficient model offered by the company, and was developed by altering the Prkdc and Il2rg genes.

“The launch of Charles River’s NCG model provides a significant opportunity to assist our clients in the development of life-saving, translational therapies,” said Dr. Iva Morse, corporate vice president, chief scientific officer, Global Research Models and Services. “The availability of this model, combined with our scientific expertise, will allow us to work with clients to advance the application of humanized studies in oncology, among other therapeutic areas.”

The NCG model was co-developed by the Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma, and transferred to Charles River in 2016. The NCG model is similar to other triple-immunodeficient models in that it is capable of hosting xenograft cells, tissue, and human immune system components, enabling researchers to further study tumor biology and immuno-oncology.